Trial Profile
A Phase III Second Line Trial of Patients With Gemcitabine Resistant Advanced Pancreatic Cancer (CONKO-003)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2021
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Fluorouracil; Folinic acid
- Indications Pancreatic cancer
- Focus Expanded access; Therapeutic Use
- Acronyms CONKO-003
- 06 Jun 2017 Results of pooled analysis of three studies including this study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 04 Nov 2008 New source identified and integrated (ClinicalTrials.gov record NCT00786058).
- 14 Oct 2008 Results published in Journal of Clinical Oncology.